Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The British Heart Foundation (BHF) has highlighted its hope that a recent grant awarded to Associate Professor Paolo Tammaro will lead to a more positive outcome for stroke survivors.

Paolo's work over the next three years, funded by an award of £250,000 from the BHF, will focus on the 'no-reflow' phenomenon whereby blood vessels blocked by clots during a stroke do not re-establish blood flow once the clot is removed. This can have a detrimental affect on a patient's recovery as tissues continue to suffer from a lack of oxygen and the brain suffers further damage.

The Tammaro group's hypothesis is that small cells called pericytes, found around capillaries, can cause this no-reflow. The group will study a protein that causes the pericytes to bond together and will target it with drugs using a rat model of stroke. If successful, the project could help identify new therapeutic targets.

Further details can be found here: https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2019/june/new-research-in-oxford-could-lead-to-improvements-in-recovery-of-stroke-survivors

Similar stories

Anthony group research offers new treatment hope for ALS patients

New research, led by the Anthony Group in Pharmacology and funded by GeNeuro, suggests a pathway to a new precision medicine approach for patients with amyotrophic lateral sclerosis (ALS). The groundbreaking findings were presented at the 35th International Symposium on ALS/MND, which took place in Montreal, Canada, from 6-8 December 2024.